An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)

Trial Profile

An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Imatinib (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms ESPHALL
  • Most Recent Events

    • 14 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2015 Planned End Date changed from 31 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 17 Feb 2015 Planned primary completion date changed to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top